A recent meta-analysis [33] reported generally higher circulating resistin levels in MASLD compared with controls, but lower resistin levels in biopsy-confirmed MASH cases, suggesting a decrease in resistin with increasing disease severity and possible progression of fibrosis. This evidence concerns the gene RETN and metabolic dysfunction-associated steatotic liver disease.